Description
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Lung Cancer (LUNG-MAP Sub-Study)
This trial is available at multiple Sutter Locations. Please contact one of the following about Study SWOG S1900G
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
PAMF/Fremont: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: SIMR@sutterhealth.org
Modesto: Stephanie Edmondson edmondsons@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo: Stephanie Casal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org